This study tests how well a new drug, MET097, helps people with obesity or being overweight and type 2 diabetes (T2DM) lose weight. The drug is a GLP-1 receptor agonist, which means it helps control insulin levels in the body. Participants will receive either MET097 or a placebo (a fake treatment) once a week through a shot under the skin for 28 weeks. After this, they will be checked for 4 weeks. Only adults aged 18-75 with a body mass index (BMI) between 27 and 50 can join. They must have had T2DM for at least 3 months and a stable weight before starting. People with certain health problems, like heart disease or specific types of cancer, cannot join.
- This study lasts 28 weeks, with an additional 4-week follow-up.
- Participants receive weekly treatments and need regular check-ups.
- Participants are randomly assigned to MET097 or placebo groups.
If you qualify and join, this study might help you learn about weight loss options and how MET097 affects your T2DM and weight.